A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma-Reference-Cited by-同舟云学术

A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma

Published:2019-11 Issue:9 Volume:145 Page:2535-2546
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Kim Sang‐Soo¹²,Harford Joe B.²,Moghe Manish¹,Slaughter Tiffani²,Doherty Caroline¹,Chang Esther H.¹^ORCID

Affiliation:

1. Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University Medical Center Washington DC

2. SynerGene Therapeutics, Inc. Potomac MD

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32531

Reference46 articles.

1. Malignant Gliomas in Adults

2. Current state of immunotherapy for glioblastoma

3. Immunotherapy of Primary Brain Tumors: Facts and Hopes

4. Cancer immunotherapy comes of age

5. Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development;Neuro-Oncology;2024-07-11

2. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape;European Journal of Pharmaceutics and Biopharmaceutics;2024-07

3. Rational Design of Lipid-Based Vectors for Advanced Therapeutic Vaccines;Vaccines;2024-05-31

4. Glioblastoma Therapy: Past, Present and Future;International Journal of Molecular Sciences;2024-02-21

5. Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment;Biomedicine & Pharmacotherapy;2024-02